CTOs on the Move

Max International

www.maxgxl.com

 
Max International is a Midvale, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.maxgxl.com
  • 7090 Union Park Ctr Ste 500
    Midvale, UT USA 84047
  • Phone: 801.562.8440

Executives

Name Title Contact Details

Similar Companies

United Digestive

United Digestive is a practice management organization that partners with physicians and gastroenterology practices nationwide to provide strong operational infrastructure and high-quality patient care.

All American Health Care Services

All American Health Care Services is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aurident Inc

Aurident Inc is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syneron

Syneron Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Syneron Inc. is based in Irvine, CA. You can find more information on Syneron Inc. at www.syneron.com

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.